Trial Profile
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs ABT 751 (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- 02 Jul 2019 Status changed from active, no longer recruiting to completed.
- 15 Oct 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Jan 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.